Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells

Bioorg Med Chem Lett. 2017 Apr 1;27(7):1561-1565. doi: 10.1016/j.bmcl.2017.02.033.

Christopher Sherer ¹, Ibrahim Tolaymat ², Farzana Rowther ³, Tracy Warr ³, Timothy J Snape ⁴

Affiliations

1 School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Maudland Building, Preston, Lancashire PR1 2HE, UK.
2 Faculty of Medical Science, Anglia Ruskin University, Bishop Hall Lane, Chelmsford, Essex CM1 1SQ, UK.
3 Brain Tumour Research Centre, University of Wolverhampton, Wulfruna Street, Wolverhampton WV1 1LY, UK.
4 School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Maudland Building, Preston, Lancashire PR1 2HE, UK. Electronic address: tjsnape@uclan.ac.uk.

PMID: 28256372 DOI: 10.1016/j.bmcl.2017.02.033

Abstract

The prognosis for glioblastoma patients is, at best, poor, with the median time of survival after diagnosis measured in months. As such, there is much need for the rapid development of potent and novel treatments. Herein, we report our preliminary findings on the SAR of a series of indole-3-carbinol and related fragments and reveal a potent lead with low micromolar activity against a particularly resistant glioblastoma Cell Culture, providing a new platform for future development of a new therapy in this area.

Keywords

3,3′-Diindoloylmethane; Cancer; Glioblastoma; Indole-3-carbinol; SAR.

Name
Email *

	Sorry, but the email address you supplied was invalid.